



Drug Quantity Management – Per Rx Immunosuppressive Agents – Rezurock™ (belumosudil tablets)

Table of Contents

National Formulary Medical Necessity 1
 Conditions Not Covered.....2
 Background.....2
 References2
 Revision History.....2

Product Identifier(s)

Effective 1/1/23 to 3/21/23: 109263
Effective 3/22/23: 96906

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

This Drug Quantity Management program has been developed to prevent stockpiling and waste, and address potential order entry error of Rezurock. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per Rx*	Home Delivery Maximum Quantity per Rx
Rezurock™ (belumosudil tablets)	200 mg tablets	30 tablets	90 tablets

* Based on prescribing information, 30 of the 200 mg tablets are adequate for a 30-day supply. Exceptions can be made for individuals taking strong cytochrome P450 (CYP)3A inducers or proton pump inhibitors.

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

1. If the individual is taking Rezerox with a strong cytochrome P450(CYP)3A inducer OR with a proton pump inhibitor, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery.
Note: CYP3A4 inducers include, but are not limited to, rifampin, carbamazepine, phenobarbital, phenytoin, rifabutin, rifapentine, and St. John's Wort. Examples of proton pump inhibitors include, but are not limited to, lansoprazole, omeprazole, rabeprazole, esomeprazole, pantoprazole, and dexlansoprazole.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Rezerox, a kinase inhibitor, is indicated for the treatment of patients ≥ 12 years of age with **chronic graft-versus-host disease (GVHD)** after failure of at least two prior lines of systemic therapy.¹

Dosing

The recommended dose of Rezerox is 200 mg given orally once daily until progression of chronic GVHD that requires new systemic therapy.¹ Rezerox tablets should be swallowed whole; do not cut, crush, or chew. The dose of Rezerox should be increased to 200 mg twice daily when it is co-administered with strong cytochrome P450(CYP)3A inducers or proton pump inhibitors.

Availability

Rezerox is available as 200 mg tablets in bottles of 30.¹

References

1. Rezerox™ tablets [prescribing information]. Warrendale, PA: Kadmon; July 2021.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	No criteria changes. Policy was updated to include the existing quantity limits when the product is obtained via home delivery.	09/14/2022

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.